Phase 2 Study of the Oral Hypoxia-Inducible Factor 2α (Hif-2Α) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (Ccrcc).
JOURNAL OF CLINICAL ONCOLOGY（2021）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined